Annemiek van Ommen-Nijhof
YOU?
Author Swipe
View article: Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial Open
The SONIA trial was registered at ClinicalTrials.gov (NCT03425838).
View article: Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer Open
View article: Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer Open
View article: Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S1. Overview per patient.
View article: Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S2. Evaluated marker gene sets.
View article: Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Purpose:To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included…
View article: Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S4. Mutational landscape stratified by cohort.
View article: Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S3. Correlation between TML and TMB.
View article: Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S4. Mutational landscape stratified by cohort.
View article: Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Data from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Purpose:To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included…
View article: Table S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S4. Adverse events.
View article: Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S3. Representativeness of study participants.
View article: Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S1. Overview per patient.
View article: Figure S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S2. Best overall responses for all evaluable patients.
View article: Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S3. Correlation between TML and TMB.
View article: Figure S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S2. Best overall responses for all evaluable patients.
View article: Figure S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S1. CONSORT flow diagram.
View article: Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S2. Evaluated marker gene sets.
View article: Figure S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Figure S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Figure S1. CONSORT flow diagram.
View article: Table S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S4. Adverse events.
View article: Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Table S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Table S3. Representativeness of study participants.
View article: Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol Open
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing–based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients include…
View article: Intensified Alkylating Chemotherapy for Patients with Oligometastatic Breast Cancer Harboring Homologous Recombination Deficiency: Primary Outcomes from the Randomized Phase III Oligo Study
Intensified Alkylating Chemotherapy for Patients with Oligometastatic Breast Cancer Harboring Homologous Recombination Deficiency: Primary Outcomes from the Randomized Phase III Oligo Study Open
View article: Survival and prognostic factors in oligometastatic breast cancer
Survival and prognostic factors in oligometastatic breast cancer Open
View article: Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors
Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors Open
View article: 257P Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP)
257P Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP) Open
View article: Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors
Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors Open
PurposeAromatase inhibitors (AIs) are an important component of the adjuvant treatment of hormone receptor positive breast cancer (BC) but concerns regarding their cardiovascular safety remain. In this cross-sectional study nested in a bre…
View article: A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning
A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning Open
View article: Erratum to “Prognostic factors in patients with oligometastatic breast cancer – A systematic review”. [Cancer treatment Rev. 91 (2020) 102114]
Erratum to “Prognostic factors in patients with oligometastatic breast cancer – A systematic review”. [Cancer treatment Rev. 91 (2020) 102114] Open
View article: Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial Open